secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-03-26T23:59:59+00:00
Accession:  0001140361-24-015318
Event type: regulatory
Sentiment:  positive
Materiality: 0.40
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics regains Nasdaq compliance on audit committee composition
--------------------------------------------------------------------------

- Received Nasdaq letter on March 22, 2024, confirming regained compliance with Listing Rule 5605.
- Non-compliance was previously disclosed on Jan 17, 2024, due to lack of three independent directors.
- Compliance restored on March 20, 2024, with appointment of Rodney Nussbaum to Audit Committee.
- No further deficiencies; shares continue trading on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/0001140361-24-015318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124015318/ef20025179_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-015318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer